Biopsy

Body Vision Medical Announces Successful Validation of LungVision™ System with Fujifilm's Range of Surgical C-arms

Retrieved on: 
Tuesday, March 5, 2024

CAMPBELL, Calif., March 5, 2024 /PRNewswire/ -- Body Vision Medical, a leader in AI-driven, intraoperative imaging, announced today the successful validation of Body Vision's LungVision™ system with FUJIFILM Healthcare Americas Corporation's Persona line of C-arms and FDR Cross two-in-one fluoroscopy C-arm and portable digital radiography solution.

Key Points: 
  • CAMPBELL, Calif., March 5, 2024 /PRNewswire/ -- Body Vision Medical, a leader in AI-driven, intraoperative imaging, announced today the successful validation of Body Vision's LungVision™ system with FUJIFILM Healthcare Americas Corporation's Persona line of C-arms and FDR Cross two-in-one fluoroscopy C-arm and portable digital radiography solution.
  • Body Vision Medical's LungVision™ system uses artificial intelligence (AI) to transform X-ray images from any C-arm into real-time, intraoperative CT scans.
  • "This validation further demonstrates the power of an AI-driven imaging platform like LungVision™ that enables physicians to agnostically leverage our image-guided navigation and real-time imaging with the bronchoscopy platform and C-arm of their choice," said David Webster, CEO of Body Vision Medical.
  • "We're elated to see the successful validation of our C-arm platforms with Body Vision's leading LungVision™ system to synergistically provide the visualization needed by bronchoscopists during navigation bronchoscopy".

Body Vision Medical Signs Distribution Agreement with DK Healthcare Co., Ltd.

Retrieved on: 
Tuesday, February 27, 2024

CAMPBELL, Calif., Feb. 27, 2024 /PRNewswire/ -- Body Vision Medical, a leader in AI-driven, intraoperative imaging, announced today it has signed an exclusive distribution agreement with DK Healthcare Co., Ltd. to expand access of its cutting-edge LungVision™ real-time, intraoperative CT imaging system to South Korea.

Key Points: 
  • CAMPBELL, Calif., Feb. 27, 2024 /PRNewswire/ -- Body Vision Medical, a leader in AI-driven, intraoperative imaging, announced today it has signed an exclusive distribution agreement with DK Healthcare Co., Ltd. to expand access of its cutting-edge LungVision™ real-time, intraoperative CT imaging system to South Korea.
  • LungVision™ uses artificial intelligence (AI) to transform any C-arm fluoroscope into a cone-beam CT (CBCT) imaging system with advanced navigation capabilities.
  • "South Korea has one of the world's most aggressive lung cancer detection and diagnosis programs," said David Webster, CEO of Body Vision Medical.
  • Body Vision Medical aims to expand lung patient access to LungVision™ into 60 markets by 2025 and, with this most recent distributorship signing, have a distribution footprint in 38 countries around the world.

Volpara to Highlight Growing AI Suite for Mammography at ECR 2024, Including New Lunit Distribution Agreement

Retrieved on: 
Wednesday, February 21, 2024

WELLINGTON, New Zealand, Feb. 21, 2024 /PRNewswire/ -- Volpara Health Technologies Ltd. (ASX: VHT), a global leader in software for the early detection and prevention of cancer, announced a distribution agreement to resell Lunit's AI solutions for mammography. Lunit's AI-powered Lunit INSIGHT for early detection of breast cancer will be featured as part of the company's expanded software suite at the 2024 European Congress of Radiology (ECR). The suite also includes tools for assessing breast density, evaluating cancer risk, and ensuring mammography quality.

Key Points: 
  • Volpara and Lunit® commenced negotiating this distribution agreement prior to entering into a Scheme Implementation Agreement on 14 December 2023 (SIA).
  • This distribution agreement is important to Volpara's ongoing business regardless of whether Lunit acquires Volpara as contemplated in the SIA and allows Volpara to sell Lunit's products immediately.
  • "The collaboration between Volpara and Lunit marks a significant milestone in the evolution of mammography solutions," said Brandon Suh, CEO of Lunit.
  • Volpara will also be presenting "Trustworthy AI for personalised breast cancer screening" in ECR's AI Theatre on Wednesday, February 28 at 16:15.

Groundbreaking Live Clinical Cases Completed with the Single Pass KRONOS Biopsy Closure Device

Retrieved on: 
Monday, February 19, 2024

In the initial case, a kidney biopsy was performed under CT guidance utilizing the 22cm Single Pass KRONOS device and a 13cm biopsy needle.

Key Points: 
  • In the initial case, a kidney biopsy was performed under CT guidance utilizing the 22cm Single Pass KRONOS device and a 13cm biopsy needle.
  • In the second case, an 80-year-old female underwent a liver biopsy utilizing a 17cm Single Pass KRONOS device and ultrasound guidance.
  • The success of these initial real-life cases highlights the immense potential of the Single Pass KRONOS biopsy closure cauterization device.
  • With its exceptional performance and ease of use, the Single Pass KRONOS device is poised to revolutionize the field of biopsy closure.

Kidney Patients Target Medicare Transplant Double Standard

Retrieved on: 
Friday, February 9, 2024

WASHINGTON, Feb. 9, 2024 /PRNewswire/ -- Today, the American Association of Kidney Patients (AAKP), the largest and oldest kidney patient organization in the nation, issued an Official Statement (appears below) and an AAKP Closer Look report highlighting a new, double standard and unequal access for Medicare kidney transplant recipients who rely upon molecular blood tests for organ health surveillance and the identification of early organ rejection. Kidney disease and kidney failure disproportionately impact minority Americans. Federal data consistently demonstrates that, among historically disadvantaged communities, there are tremendous barriers and lack of opportunity to receive a kidney transplant and furthermore, re-transplantation when a donor organ fails.

Key Points: 
  • The new restrictions severely limit Medicare patients and transplant professionals from accessing molecular blood tests, covered by Medicare and utilized since 2017.
  • It is absolutely clear this is a new double standard for Medicare transplant recipients.
  • Today, Medicare patients with a kidney transplant in South Carolina and across the nation face the new reality of unequal treatment to protect their precious gifts of life.
  • Their failed leadership has empowered unelected, unaccountable, and faceless for-profit contractors to make life and death decisions that negatively impact kidney transplant patients on Medicare.

Madrigal Pharmaceuticals Announces Publication of the Phase 3 MAESTRO-NASH Trial of Resmetirom in the New England Journal of Medicine

Retrieved on: 
Thursday, February 8, 2024

NASH is a leading cause of liver-related mortality and an increasing burden on healthcare systems globally.

Key Points: 
  • NASH is a leading cause of liver-related mortality and an increasing burden on healthcare systems globally.
  • Resmetirom received Breakthrough Therapy designation from the FDA and is under review to become the first medicine approved to treat patients with NASH with liver fibrosis.
  • Approximately 50% of patients treated with resmetirom 100 mg with biopsies at Week 52 showed either NASH resolution or fibrosis improvement.
  • More than 80% of patients with biopsies at Week 52 had either fibrosis reversal or no progression of fibrosis.

Central California’s Community Regional Medical Center is the First in the State to Offer Next Generation Robotic Bronchoscopy for Early Diagnosis and Treatment of Lung Cancer

Retrieved on: 
Tuesday, January 30, 2024

Community Regional is the first hospital in California to use this new technology.

Key Points: 
  • Community Regional is the first hospital in California to use this new technology.
  • Lung cancer is the second most common cancer in the United States and the leading cause of cancer deaths in the country.
  • But today, it can be difficult for physicians to properly find and biopsy lung nodules, delaying diagnosis and complicating treatment.
  • “Lung cancer can be a particularly lethal killer in the periphery of the lung, where it’s difficult to locate and remove,” said Dr. Hegde.

500th Use of the Galaxy System™ in the United States Conducted at CHI Memorial in Tennessee

Retrieved on: 
Wednesday, January 24, 2024

SAN CARLOS, Calif., Jan. 24, 2024 (GLOBE NEWSWIRE) -- Medical robotics innovator Noah Medical today announced that the 500th use of its Galaxy System in the United States was conducted at CHI Memorial in Chattanooga by Dr. Krish Bhadra.

Key Points: 
  • SAN CARLOS, Calif., Jan. 24, 2024 (GLOBE NEWSWIRE) -- Medical robotics innovator Noah Medical today announced that the 500th use of its Galaxy System in the United States was conducted at CHI Memorial in Chattanooga by Dr. Krish Bhadra.
  • CHI Memorial is also the first hospital in Tennessee to adopt the Galaxy technology.
  • The procedure marks an important step for Noah in the commercial rollout of its image-integrated robotic assisted bronchoscopy system in the U.S.
  • To learn more about Noah Medical and the Galaxy System, please visit noahmed.com .

Precipio’s Q4-2023 Cash Burn From Operations (unaudited) drops below $100K for the full quarter

Retrieved on: 
Tuesday, January 23, 2024

Cash Burn From Operations (CBFO) declined by over 90% from the previous quarter, from approximately $1M/quarter in Q3-2023 to below $100k/quarter in the following recent quarter Q4-2023.

Key Points: 
  • Cash Burn From Operations (CBFO) declined by over 90% from the previous quarter, from approximately $1M/quarter in Q3-2023 to below $100k/quarter in the following recent quarter Q4-2023.
  • Precipio’s end of quarter cash balance changed from approximately $1.5M at the end of Q3-2024, to approximately $1.4M as of Dec 31, 2023.
  • Notwithstanding the above mentioned “seasonal” effects, the Q4-2023 CBFO results demonstrate the company’s ability to approach cash flow breakeven.
  • “Seeing the results of our business impact cash flow in this way is extremely promising, and further validates our business model.

Sagimet Biosciences Announces Positive Topline Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 NASH

Retrieved on: 
Monday, January 22, 2024

SAN MATEO, Calif., Jan. 22, 2024 (GLOBE NEWSWIRE) --  Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors designed to target dysfunctional metabolic and fibrotic pathways, today announced positive topline results from its FASCINATE-2 Phase 2b clinical trial of denifanstat versus placebo in biopsy-confirmed non-alcoholic steatohepatitis (NASH) patients with stage 2 or stage 3 fibrosis (F2/F3) at week 52. In this trial, denifanstat, an oral, selective FASN inhibitor, showed statistically significant improvements relative to placebo on both of the primary endpoints of NASH resolution without worsening of fibrosis with ≥2-point reduction in NAS, and ≥2-point reduction in NAS without worsening of fibrosis. Denifanstat-treated patients also showed statistically significant fibrosis improvement by ≥ 1 stage with no worsening of NASH, and a greater proportion of MRI-derived proton density fat fraction (MRI-PDFF) ≥30% responders relative to placebo.

Key Points: 
  • “Denifanstat is designed to reduce the three main drivers of NASH, including fat accumulation, inflammation, and fibrosis, both independently and in parallel.
  • “Sagimet is committed to creating novel approaches to target dysfunctional metabolic pathways, and we believe these positive results represent a major advancement in that endeavor.
  • “Denifanstat is the only FASN inhibitor currently in clinical development for the treatment of NASH with related fibrosis.
  • Moreover, the safety profile supports the further development of denifanstat in NASH patients.”